$17.49-5.6%Nov 13 close
Reported results on November 10, 2026; they are not in these figures yet.
Figures through March 31, 2026, from the 6-K filed May 12, 2026
The quarter ending March 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toMar 31, 2026 | 3 months toMar 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $305.1M | $195.1M | +56.42% |
| Profit | -$54.3M | -$100.9M | +46.19% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We made meaningful progress during the third quarter, expanding the reach of CARVYKTI and advancing our pipeline,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
The quote and the company description come from the 6-K Legend Biotech Corp filed on November 10, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Legend Biotech Corp reported on November 10, 2026. We are fetching the call transcript; its summary follows once the transcript is in.